SCHEMBL706823

SCHEMBL706823

O=C(O)CN(CC(=O)O)Cc1cc(C#Cc2ccc(N=C=S)cc2)cc(CN(CC(=O)O)CC(=O)O)n1

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.41
FFAR1 O14842 9/20 0.35
P2RY6 Q15077 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
MIF P14174 1/20 0.33
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
FFAR4 Q5NUL3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15630169 0.95 HSD17B10 (0.38) HSD17B10FFAR1P2RY6EGLN1CA1
SCHEMBL15630171 0.95 HSD17B10 (0.38) HSD17B10FFAR1P2RY6EGLN1CA1
SCHEMBL12293196 0.93 HSD17B10 (0.36) HSD17B10FFAR1EGLN1
SCHEMBL2383871 0.92 HSD17B10 (0.36) HSD17B10FFAR1
SCHEMBL19013118 0.89 HSD17B10 (0.36) HSD17B10
SCHEMBL9356539 0.88 HSD17B10 (0.34) HSD17B10FFAR1
SCHEMBL890271 0.88 HSD17B10 (0.34) HSD17B10P2RY6CA1CA2
SCHEMBL15906283 0.86 HSD17B10 (0.32) HSD17B10EGLN1
SCHEMBL14721509 0.84 FFAR1 (0.38) HSD17B10FFAR1
SCHEMBL4598913 0.82 P2RY6 (0.50) HSD17B10P2RY6MIF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630796-B2 System, device, and method for single-cell encapsulation and culture UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2026-05-19 US disclosed
EP-4741825-A1 TEST KIT Lifetrek Inc. (JP) 2026-05-13 EP disclosed
WO-2025013724-A1 TEST KIT ライフトレック株式会社 2025-01-16 WO disclosed
US-20240201190-A1 COMPOSITIONS AND METHODS OF DIAGNOSING PANCREATIC CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
CN-118191342-A Quantitative detection kit and detection method for soluble fms-like tyrosine kinase-1 广州市丰华生物股份有限公司 2024-06-14 CN disclosed
US-11726091-B2 Compositions and methods of diagnosing pancreatic cancer THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-15 US disclosed
US-20230174912-A1 SYSTEM, DEVICE, AND METHOD FOR SINGLE-CELL ENCAPSULATION AND CULTURE UNIVERSITY OF MARYLAND, COLLEGE PARK 2023-06-08 US disclosed
WO-2021216789-A1 SYSTEM, DEVICE, AND METHOD FOR SINGLE-CELL ENCAPSULATION AND CULTURE UNIVERSITY OF MARYLAND, COLLEGE PARK (US) 2021-10-28 WO disclosed
US-11112409-B2 Systems and compositions for diagnosing pathogenic fungal infection and methods of using the same THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-09-07 US disclosed
US-10808024-B2 Antibodies against immunocomplexes comprising cyanobacterial cyclic peptide hepatotoxins TURUN YLIOPISTO (FI) 2020-10-20 US disclosed
US-20040043502-A1 Membrane-based assay devices that utilize time-resolved fluorescence KIMBERLY-CLARK WORLDWIDE, INC. 2004-03-04 US disclosed
EP-0938678-B1 METHOD AND KIT FOR THE DIAGNOSIS OF TROPONIN I ABOATECH AB OY (FI) 2003-09-03 EP disclosed
US-20030040024-A1 Method and kit for the diagnosis of troponin I HYTEST LTD. (FI) 2003-02-27 US disclosed
US-6429026-B1 One-step all-in-one dry reagent immunoassay INNOTRAC DIAGNOSTICS OY (FI) 2002-08-06 US disclosed
EP-1003778-A1 ISOLATED OSTEOCALCIN FRAGMENTS Hellman, Jukka (FI) 2000-05-31 EP disclosed
EP-0938678-A1 METHOD AND KIT FOR THE DIAGNOSIS OF TROPONIN I OY Aboatech AB (FI) 1999-09-01 EP disclosed
WO-1999009058-A1 ISOLATED OSTEOCALCIN FRAGMENTS HELLMAN JUKKA (FI) 1999-02-25 WO disclosed
EP-0892927-A1 ONE-STEP ALL-IN-ONE DRY REAGENT IMMUNOASSAY Pettersson, Kim (FI) 1999-01-27 EP disclosed
WO-1997049994-A1 METHOD AND KIT FOR THE DIAGNOSIS OF TROPONIN I OY ABOATECH AB (FI) 1997-12-31 WO disclosed
WO-1997038311-A1 ONE-STEP ALL-IN-ONE DRY REAGENT IMMUNOASSAY PETTERSSON KIM (FI) 1997-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10808024-B2 Antibodies against immunocomplexes comprising cyanobacterial cyclic peptide hepatotoxins VIP, HCCS, C3AR1 HSD17B10 544/4885FFAR1 4462/4885P2RY6 4397/4885
US-12630796-B2 System, device, and method for single-cell encapsulation and culture CD44, KIT, EPCAM HSD17B10 4208/4885FFAR1 3763/4885P2RY6 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.